Lecanemab: 8 agencies, 2023–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Every decisive outcome on file for lecanemab is negative — 4 of them, across 4 agencies.
The record spans 2.9 years, opening at AWMSG (Wales) on 24 Mar 2023 and running to 25 Feb 2026.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 8 of 8 records date from 2023 or later.
Against its own class, lecanemab is an outlier: 0% of its decisive outcomes were positive, where molecules sharing ATC class N06D average 38%.
1 of these 8 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess lecanemab, on 24 Mar 2023; CIPM (Spain) did not open a file until 25 Feb 2026 — a moderate spread of 2.9 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
8 of the 18 agencies in this archive hold a record for lecanemab.
The full ledger for lecanemab reads 4 not recommended, 1 no benefit, 1 advice and 1 appraised, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 19 Feb 2026 | Leqembi — benefit assessment §35a | added benefit: not proven | source |
| ZIN (Netherlands) | 13 Feb 2026 | Advies - niet vergoeden lecanemab (Leqembi ®) voor de behandeling van Alzheimer | not reimbursed | source |
| DMC (Denmark) | 17 Dec 2025 | Voksne patienter med klinisk diagnosticeret let kognitiv svækkelse og let demens som følge af Alzheimers sygdom (tidlig … | Ikke anbefalet | source |
| SMC (Scotland) | 7 Jul 2025 | For treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients that are apolipoprotein E ɛ 4 (ApoEɛ4) heterozygotes or non-carr… | not recommended | source |
| PBAC (Australia) | 2024 | Early Alzheimer disease (EAD) | Not Applicable | source |
3 further decisions for lecanemab, across 3 agencies, are not shown here. They include the most recent record on file, 25 Feb 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- memantine — same ATC class N06D — Psychoanaleptics
- donepezil — same ATC class N06D — Psychoanaleptics
- donanemab — same ATC class N06D — Psychoanaleptics
- galantamine — same ATC class N06D — Psychoanaleptics
- rivastigmine — same ATC class N06D — Psychoanaleptics
- dydrogesterone — also decided by CIPM in 2026Q1
Coverage: 8 decisions for lecanemab from 8 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class N06D — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.